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iith a lifetime 1 in 4 risk of its development (1), atrial
brillation (AF) continues to be the most common cardiac
rrhythmia that impairs quality of life and contributes to
ncreased susceptibility to heart failure, hospitalization,
troke, and mortality, costing society more than $15 billion
nnually (2,3). With the rapid increase in the number of
lderly patients (4) and cardiovascular comorbidities (5), a
-fold increase in the prevalence of AF (from 2.3 million to
5.9 million) is projected (6), highlighting the magnitude of
he problem and the far-reaching implications that the
pidemic of AF will have on the health and economics of
See page 725
he country. Thus, an urgent need exists to better under-
tand clinical factors and the basic biology that predispose to
F and its progression and associated complications so that
ffective preventive strategies can be implemented to reduce
he burden of AF on society. AF is a heterogeneous disorder
ith variable etiology, clinical profile, and natural history
2). From a clinical perspective, AF has been broadly
lassified as paroxysmal, persistent (or long-lasting), and
ermanent, depending on the duration of symptoms and its
ropensity to terminate by itself, terminate with electrical or
harmacological intervention, or not terminate at all (2,7).
he electrophysiological basis for the initiation and/or
aintenance of AF varies depending on age, the presence of
nderlying heart disease, and other modulating factors. In
he majority of patients, AF occurs in the setting of
tructural heart disease, with only a small percentage exhib-
ting AF as a primarily electrical disorder (2,8). Changes in
emodynamic, mechanical, neurohumoral, metabolic, and
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ranslation Marriott Mitochondrial Medicine Award, and Angel and Paul Harvey2
esearch Endowment for CardioGerontology Research Laboratory at Mayo Clinic
rizona.nflammatory factors that accompany aging or aging-
ssociated diseases (9), such as heart failure, valvular heart
isease, hypertension, myocardial infarction, pulmonary dis-
ase, and diabetes contribute to the development of AF, yet
he common mechanistic link between these factors and the
evelopment of the substrate for AF or its progression is not
ully understood (10).
In this issue of the Journal, de Vos et al. (11) report the
esults of their investigation on the clinical correlates of AF
rogression and prognosis in patients enrolled in the Euro
eart Survey of AF. The Euro Heart Survey enrolled 5,333
dult patients between 2003 and 2004 in 182 hospitals
mong 35 different European countries and represents a
nique overview of real-life AF management within cardi-
logy practices across Europe (12). Their report is on 1,219
atients with paroxysmal or first detected AF in whom sinus
hythm restored spontaneously or after pharmacological
reatment during admission and who had a known rhythm
tatus at 1-year follow-up. Progression of AF to persistent
r long-lasting forms occurred in 178 (15%) patients. These
atients were older and had more underlying cardiovascular
isease and other comorbidities. On multivariate analysis,
ATCH (hypertension, age older than 75 years, previous
ransient ischemic attack or stroke, chronic obstructive
ulmonary disease, and heart failure) were identified as
ndependent predictors of AF progression. Using the re-
ression coefficient as a benchmark, the investigators came
p with the HATCH score to predict the probability of
rogression of AF. With an increasing HATCH score, the
roportion of patients in whom AF progressed to long-
asting forms was significantly higher with a greater number
f hospital admissions and major adverse cardiovascular
vents compared with those with fewer of these risk factors.
The strength of this study is the provision of information
bout AF management and progression in patients in 35
uropean countries in real-life situations and the develop-
ent of a risk prediction system for progression of parox-
smal or first detected AF. The major limitation is that
nformation is provided only on 50% of patients (1,219 of
,495) who were initially included in the survey with a first
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February 23, 2010:732–4 Progression of Paroxysmal AFpisode of AF or paroxysmal AF (12). The patients who
ere not included could have gone either way (i.e., AF
rogressed or remained paroxysmal), and, hence, the re-
orted results could under- or overestimate the true pro-
ression rate. In a population of AF patients referred to
ardiology practices within university (majority of patients)
nd nonuniversity settings in 35 different (western, central,
nd Mediterranean) European countries with variable facil-
ties and management left to the usual local institutional
ractices, the interpretation of the data and generalizability
o AF patients in the community become difficult. This,
ombined with the short follow-up period and definition of
aroxysmal AF used (12) diminishes the robustness of the
onclusion. The authors included a significant number of
atients with AF who required pharmacological cardiover-
ion for restoration of sinus rhythm in paroxysmal AF,
hich, by standard definition, would have been classified as
ersistent AF (2). These patients could have a different
lectrophysiological substrate or natural history from those
ho spontaneously converted to sinus rhythm and thus may
ave substantially influenced progression analysis. Differ-
nces in the definitions used and misclassification of AF
ubtype at enrollment, as previously reported (12), also
ake comparison with other studies difficult. No informa-
ion about the date of onset and duration of AF before
nrollment is provided. A population with new-onset or
ecently diagnosed AF could have provided more useful
nformation on progression to long-lasting AF. In addition,
he use of beta-blockers and other cardiac medicines seems
o be low, considering the substantial number of patients
ith coronary artery disease, hypertension, and heart failure
ho were included (13), raising the concern that these patients
ay have been undertreated, thus complicating the differenti-
tion of atrial substrate progression due to coronary artery
isease, heart failure, or remodeling solely caused by rhythm
isturbance or uncontrolled ventricular rate response.
Although no new insights into the mechanisms of AF
r risk predictions are reported, the proposed HATCH
cheme for AF progression seems to be a useful scoring
ystem and is the major strength of the article. The
triking similarity to CHADS2 (congestive heart failure,
ypertension, age [75 years and older], diabetes mellitus,
nd a history of stroke or transient ischemic attack) score for
isk of thromboembolic events (14) is interesting. Both
eflect the advanced age of the AF population and comor-
idities, such as the presence of heart failure, hypertension,
revious stroke/transient ischemic attack, chronic obstruc-
ive pulmonary disease (for progression vs. diabetes mellitus
or thromboembolic risk), highlighting factors associated
ith an advanced substrate for AF progression and its
omplications. The HATCH score may help to identify
atients who are at high risk of progression and hence may
e followed more closely than they otherwise would be. The
uthors suggest that the HATCH score may also identify
he population in which the rate versus rhythm control
pproach should be used, because antiarrhythmic agentsere unable to prevent progression of AF in their popula-
ion. In the absence of randomization to specific treatment
trategies and treatment decisions left to the preference of
he attending cardiologist (12), the conclusion about the
ack of effectiveness of antiarrhythmic agents in preventing
rogression needs to be made with caution. The HATCH
core may help, but may not be the sole determinant of the
ecision for initiating antiarrhythmic therapy, as the treat-
ent for paroxysmal AF needs to be individualized based on
he presence of symptoms associated with frequent recur-
ences (2). The findings of the study again reinforce
revious recommendations regarding frequent monitoring
15) for the development and treatment of comorbidities (2)
hat may accelerate AF progression and predispose to its
omplications.
In summary, this study validates the risk factors reported
reviously for AF progression (2) in a referral population of
ardiology practices within a widely diverse geopolitical area
n Europe. The HATCH score seems to be a useful tool to
redict the progression of AF but should be validated in
ther populations with a longer follow-up period before it
an be applied in clinical practice. The major challenge
aised by this and other studies identifying risk factors for
he development and progression of AF is to focus our
fforts on identification of common mechanistic links be-
ween these factors and the molecular substrate that pro-
otes the development of AF and its progression, so that
ffective strategies can be developed to prevent AF and its
ssociated complications.
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